73 related articles for article (PubMed ID: 2447434)
1. Altered adrenergic control in hypercholesterolemia.
Ohanian J; Nicolosi RJ; Vatner SF; Graham RM; Kowala MC; Young MA
J Cardiovasc Pharmacol; 1987; 10 Suppl 9():S11-5. PubMed ID: 2447434
[TBL] [Abstract][Full Text] [Related]
2. Effects of calcium antagonists and adrenergic antihypertensive drugs on plasma lipids and cellular cholesterol metabolism.
Krone W; Müller-Wieland D; Nägele H; Behnke B; Greten H
J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S199-202. PubMed ID: 2455133
[TBL] [Abstract][Full Text] [Related]
3. Metabolic changes during antihypertensive therapies.
Krone W; Nägele H
J Hum Hypertens; 1989 Dec; 3 Suppl 2():69-73; discussion 74. PubMed ID: 2575177
[TBL] [Abstract][Full Text] [Related]
4. Regulation of lipoprotein metabolism by adrenergic mechanisms.
Dzau VJ; Sacks FM
J Cardiovasc Pharmacol; 1987; 10 Suppl 9():S2-6. PubMed ID: 2447436
[TBL] [Abstract][Full Text] [Related]
5. Platelet alpha 2-adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation.
Baldassarre D; Mores N; Colli S; Pazzucconi F; Sirtori CR; Tremoli E
Clin Pharmacol Ther; 1997 Jun; 61(6):684-91. PubMed ID: 9209252
[TBL] [Abstract][Full Text] [Related]
6. Effects of a new alpha 1-blocker, bunazosin hydrochloride, on plasma lipid components in hypertensive patients with hypercholesterolemia.
Yashiro A; Sugano M; Nakashima Y; Tasaki H; Kuroiwa A
Clin Ther; 1987; 10(1):98-106. PubMed ID: 2897239
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive drugs and blood lipids: the Oslo study.
Leren P; Eide I; Foss OP; Helgeland A; Hjermann I; Holme I; Kjeldsen SE; Lund-Larsen PG
J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S222-4. PubMed ID: 6177960
[TBL] [Abstract][Full Text] [Related]
8. Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model.
Foxall TL; Shwaery GT; Stucchi AF; Nicolosi RJ; Wong SS
Am J Pathol; 1992 Jun; 140(6):1357-63. PubMed ID: 1351367
[TBL] [Abstract][Full Text] [Related]
9. Effect of alpha/beta blockers on serum lipids.
Lehtonen A
Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):228-30. PubMed ID: 6114045
[TBL] [Abstract][Full Text] [Related]
10. Effects of alpha 1-inhibition on lipid metabolism in the rat.
Woodside WF; Swindell AC
J Cardiovasc Pharmacol; 1987; 10 Suppl 9():S27-34. PubMed ID: 2447438
[TBL] [Abstract][Full Text] [Related]
11. Anti-atherosclerotic and plasma lipid lowering effects of the novel calcium blocker with alpha 1-adrenoceptor antagonistic activity, monatepil, in high cholesterol diet-fed Japanese Macaca fuscata monkeys.
Miyazaki M; Hosoki K; Okunishi H; Ishii K; Ikeno A; Okazaki Y
Arzneimittelforschung; 1994 Mar; 44(3):288-97. PubMed ID: 8192692
[TBL] [Abstract][Full Text] [Related]
12. Terazosin: a new antihypertensive agent with favorable effects on lipids.
Luther RR
Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
[TBL] [Abstract][Full Text] [Related]
13. Effect of chronic treatment with atenolol and prazosin in streptozotocin induced diabetic rats.
Goyal RK; Bangaru RA; Lakkad NB; Rao MV
Indian J Physiol Pharmacol; 1996 Jul; 40(3):220-4. PubMed ID: 8950136
[TBL] [Abstract][Full Text] [Related]
14. The effects of antihypertensive agents on serum lipids and lipoproteins.
Lardinois CK; Neuman SL
Arch Intern Med; 1988 Jun; 148(6):1280-8. PubMed ID: 2897834
[TBL] [Abstract][Full Text] [Related]
15. [Effect of enalapril and terazosin on lipid metabolism in patients with essential arterial hypertension and accompanying hypercholesterolemia].
Ponikowski P; Hańczycowa H; Sebzda T; Jurga M; Spring A; Rotter A; Jordanek P
Wiad Lek; 1993 Apr; 46(7-8):250-4. PubMed ID: 7902632
[TBL] [Abstract][Full Text] [Related]
16. Effect of bucindolol on plasma HDL cholesterol subfractions and other plasma lipids in essential hypertensive patients.
Lehtonen A; Tanskanen A; Temmerman J
Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):448-51. PubMed ID: 2888737
[TBL] [Abstract][Full Text] [Related]
17. Cardio-protective role of terazosin is possibly mediated through alteration in thyroid function.
Jatwa R; Kar A
Eur J Pharmacol; 2006 Dec; 551(1-3):87-91. PubMed ID: 17027746
[TBL] [Abstract][Full Text] [Related]
18. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
Itskovitz HD
Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
[TBL] [Abstract][Full Text] [Related]
19. Serum lipids, lipoproteins, hemodynamics, and hemostasis in doxazosin-treated monkeys.
Karge WH; Kowala MC; Weiner EJ; Nicolosi RJ
J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S25-9; discussion S29-30. PubMed ID: 2471012
[TBL] [Abstract][Full Text] [Related]
20. Serum lipoproteins during treatment with antihypertensive drugs.
Weidmann P; de Courten M; Ferrari P; Böhlen L
J Cardiovasc Pharmacol; 1993; 22 Suppl 6():S98-105. PubMed ID: 7508069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
